Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Investment Chat Board Lawsuits -- Ignore unavailable to you. Want to Upgrade?

To: Jeffrey S. Mitchell who wrote (1248)	4/5/2001 10:01:34 PM
From: Arcane Lore	Read Replies (1) \| Respond to of 12465

Thursday April 5, 3:51 pm Eastern Time Ives Health founder charged in AIDS drug scheme By Gail Appleson, Law Correspondent NEW YORK, April 5 (Reuters) - The founder of a company that recently began selling what it touted as a breakthrough AIDS medicine has been arrested for allegedly making false claims about the product and defrauding the FDA, federal prosecutors said on Thursday. M. Keith Ives was arrested by the FBI in Oklahoma on Wednesday on a two-count complaint filed in Manhattan federal court. The complaint charges him and Ives Health Company with conspiracy and wire fraud. Claremone, Okla.-based Ives Health sells natural remedies and homeopathic medicines. The complaint alleges that the defendants made false claims about the efficacy of the product, that they introduced the drug without getting Food and Drug Administration approval and that they defrauded the agency. If convicted, Ives faces a maximum sentence of five years in prison on each of the two counts. According to the complaint, Ives Health (OTC BB:IVEH.OB - news) issued a press release on Feb. 15 stating that its T-Factor formula was successful in increasing T-Cell cell counts in HIV patients. The announcement, which was released on Business Wire, said that the results of ``this ground-breaking study come as Ives releases the drug, which has virtually no side effects, to the public on its website.'' The release quoted Ives, who is also the company's president as saying ``This is incredible news. There has been a revelation occurring in HIV healthcare that has linked T-Cell loss to immune system deficiency.'' LIFE SPAN INCREASE CLAIMED The release said that the formula, which Ives acquired in 1998, could help increase HIV patients' life span. It said that although FDA-approved drugs cost more than $25,000 a year, an annual supply of T-Factor sells for $600. The press release stated the product was based on a purported scientific research program known as the ``The Java Project'' that was supposedly conducted by Dr. Robert Slayton-Bedeen in association with the World Health Organization. The study was purportedly conducted in Jakarta, Indonesia. Ives issued another press release on Feb. 19 again touting the product. According to its web-site, T-Factor ``works by introducing highly active and effective thymus cells which trigger the chain reaction of events which cause an accelerated rate of T-cell manufacture.'' The product was said to contain "juvenile neonatal bovine calf thymus, pituitary gland, spleen, lymph gland and bone marrow. The criminal complaint said an FBI agent interviewed Dr. Michael Merson, the Dean of the School of Public Health at Yale University, who had served as the Director of the World Health Organization's Global Program on Aids from 1978 to 1995. The doctor, who continues to research HIV prevention, said he never heard of Slayton-Bedeen, the Java Project or the T-Factor product. He also said that thymus glands, supposedly one of the main ingredients in the product, have never been found to be effective in treating AIDS or HIV to his knowledge. On March 16 the Securities and Exchange Commission announced the temporary suspension of trading in Ives Health because of questions regarding the accuracy of the company's public statements. Even after the suspension, the defendants continued to post false and misleading information on Ive's website, the complaint alleged. biz.yahoo.com

To: Jeffrey S. Mitchell who wrote (1248)	8/28/2002 5:22:42 PM
From: Arcane Lore	Read Replies (1) \| Respond to of 12465

From today's SEC Digest: SEC PROCEEDINGS AGAINST IVES HEALTH COMPANY, INC. BASED ON DELINQUENT FILINGS On August 27, the Commission instituted a proceeding against Ives Health, an Oklahoma corporation, to determine whether it is appropriate and for the protection of investors to deregister Ives Health's common stock. Trading in the stock was suspended by the Commission for ten days on March 5, 2001, and the company was sued by the Commission in July 2001, as part of a civil injunctive action alleging, among other things, fraudulent press releases regarding an Ives Health product that supposedly treated HIV. The company, which defaulted in the civil injunctive action, was also charged in that action with failure to file required reports with the Commission. The company's failure to file any periodic reports since 2000 (including Forms 10-K for its years ended December 31, 2000 and 2001) is the basis for the administrative proceeding announced today. A hearing will be scheduled before an administrative law judge to determine whether the allegations contained in the Order are true, to provide Ives Health an opportunity to dispute these allegations, and to determine what sanctions, if any, are appropriate and for the protection of investors. (Rel. 34-46420; File No. 3-10871) sec.gov

To: Jeffrey S. Mitchell who wrote (1248)	1/31/2003 5:29:09 PM
From: Arcane Lore	Respond to of 12465

From today's SEC Digest: IN THE MATTER OF IVES HEALTH COMPANY, INC. An Administrative Law Judge has issued an order entering default in the Matter of Ives Health Company, Inc. The Order Instituting Proceedings (OIP) alleged that a U.S. District Court permanently enjoined Ives Health Company, Inc. from violating Sections 5(a) and 17(a) of the Securities Act of 1933 and Sections 10(b) and 13(a) of the Securities Exchange Act of 1934 and Rules 10b-5, 12b-20, 12b-25, 13a-1 and 13a-13 thereunder. The order finds the allegations in the OIP to be true and, pursuant to Section 12(j) of the Securities Exchange Act of 1934 revokes the registration of the common stock of Ives Health Company, Inc. (Rel. 34-47291; File No. 3-10871) sec.gov